🧬 CA017-078 (ENERGIZE) in resectable MIBC:

返回会议原文

返回会议

OncoDaily IO· @OncoDailyIO · X·2026-10-23 20:00· 2 天前评分70

nivolumab

正文 · 机器翻译

🧬 CA017-078 (ENERGIZE) 在可切除 MIBC 中：

围手术期 nivolumab + 新辅助 GC 对比单独 GC：
📈 pCR：39.1% 对 29.6%（无统计学意义）
⏳ EFS：HR 0.94；P=0.67
两个共同主要终点均未达标。

https://oncodaily.com/oncolibrary/immune-oncology/ca017-078-trial

#ESMO2026 #OncoDaily

91 浏览 · 0 赞 · 0 转发 · 0 回复

会议摘要

2081PNCT04949113 NCT04949113 NCT04949113按 Melanoma 对上

Emotional distress (ED) upfront neoadjuvant ipilimumab + nivolumab (IPI+NIVO) is associated with lower pathological response and toxicity

https://esmocongress.esmo.org

4736O按 Proffered paper 1: Genitourinary tumour, renal and urothelial 对上

Results from a phase 3 trial of neoadjuvant (neoadj) chemotherapy alone vs in combination with nivolumab followed by postsurgical adjuvant nivolumab in patients (pts) with muscle-invasive bladder cancer (MIBC)

https://esmocongress.esmo.org

4757RO按 Rapid oral 1: Genitourinary tumours, renal and urothelial 对上

Final pathological and radiological outcomes and initial EFS from a blinded, exploratory phase 2 trial of nivolumab ± visugromab in MIBC (GDFather-NEO)

https://esmocongress.esmo.org

LBA54按 Proffered paper: Melanoma and other skin tumours 对上

Primary analysis of HBI-8000-303: A randomized phase 3 trial of nivolumab plus HBI-8000 or placebo in advanced melanoma

https://esmocongress.esmo.org

NCT04884282NCT04884282按 - **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED) 对上

- **标题 / Title：** Efficacy of Tedopi Plus Docetaxel or Tedopi Plus Nivolumab as Second-line Therapy in Metastatic Non-small-cell Lung Cancer Progressing After First-line Chemo-immunotherapy (Combi-TED)

https://esmocongress.esmo.org

来源：OncoDaily IO · x.com